Lisanti Capital Growth LLC lifted its stake in HealthEquity, Inc. (NASDAQ:HQY - Free Report) by 467.5% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 47,100 shares of the company's stock after purchasing an additional 38,800 shares during the period. Lisanti Capital Growth LLC owned about 0.05% of HealthEquity worth $4,162,000 at the end of the most recent quarter.
Other institutional investors also recently added to or reduced their stakes in the company. Ameritas Investment Partners Inc. increased its holdings in HealthEquity by 0.3% during the fourth quarter. Ameritas Investment Partners Inc. now owns 33,856 shares of the company's stock valued at $3,248,000 after buying an additional 88 shares during the period. Smartleaf Asset Management LLC boosted its position in HealthEquity by 34.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 384 shares of the company's stock valued at $37,000 after acquiring an additional 98 shares in the last quarter. State of Michigan Retirement System increased its holdings in shares of HealthEquity by 0.5% in the 4th quarter. State of Michigan Retirement System now owns 20,722 shares of the company's stock valued at $1,988,000 after acquiring an additional 100 shares during the period. Oregon Public Employees Retirement Fund raised its position in shares of HealthEquity by 0.6% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 17,776 shares of the company's stock worth $1,706,000 after acquiring an additional 100 shares in the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its position in shares of HealthEquity by 0.6% in the 4th quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 19,286 shares of the company's stock worth $1,850,000 after acquiring an additional 106 shares in the last quarter. Hedge funds and other institutional investors own 99.55% of the company's stock.
Analysts Set New Price Targets
HQY has been the topic of several analyst reports. The Goldman Sachs Group lifted their target price on HealthEquity from $94.00 to $104.00 and gave the company a "neutral" rating in a research note on Wednesday, June 4th. JMP Securities increased their price target on shares of HealthEquity from $110.00 to $117.00 and gave the company a "market outperform" rating in a research report on Wednesday, June 4th. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of HealthEquity from $98.00 to $115.00 and gave the stock a "buy" rating in a research report on Thursday, June 5th. Royal Bank Of Canada increased their target price on shares of HealthEquity from $112.00 to $117.00 and gave the company an "outperform" rating in a research report on Wednesday, June 4th. Finally, Barrington Research raised their target price on shares of HealthEquity from $112.00 to $125.00 and gave the company an "outperform" rating in a research note on Thursday, June 5th. One investment analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, HealthEquity has an average rating of "Buy" and an average price target of $118.09.
Read Our Latest Report on HealthEquity
Insider Buying and Selling
In related news, EVP Elimelech Rosner sold 58,000 shares of HealthEquity stock in a transaction that occurred on Friday, June 6th. The stock was sold at an average price of $112.56, for a total transaction of $6,528,480.00. Following the completion of the transaction, the executive vice president directly owned 75,689 shares in the company, valued at approximately $8,519,553.84. This trade represents a 43.38% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jon Kessler sold 97,767 shares of the firm's stock in a transaction that occurred on Friday, June 6th. The stock was sold at an average price of $112.05, for a total transaction of $10,954,792.35. Following the sale, the director directly owned 75,000 shares in the company, valued at $8,403,750. The trade was a 56.59% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 304,581 shares of company stock worth $33,664,018 over the last ninety days. 1.50% of the stock is owned by corporate insiders.
HealthEquity Stock Performance
NASDAQ HQY traded down $1.61 on Wednesday, hitting $101.28. 1,315,047 shares of the company's stock traded hands, compared to its average volume of 858,669. The firm's 50-day moving average price is $98.89 and its two-hundred day moving average price is $98.12. The firm has a market capitalization of $8.76 billion, a PE ratio of 73.93, a P/E/G ratio of 1.61 and a beta of 0.49. The company has a current ratio of 4.06, a quick ratio of 4.06 and a debt-to-equity ratio of 0.50. HealthEquity, Inc. has a 1-year low of $65.01 and a 1-year high of $116.65.
HealthEquity (NASDAQ:HQY - Get Free Report) last posted its earnings results on Tuesday, June 3rd. The company reported $0.97 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.81 by $0.16. The company had revenue of $330.80 million during the quarter, compared to the consensus estimate of $322.25 million. HealthEquity had a net margin of 9.80% and a return on equity of 11.01%. During the same period in the previous year, the firm posted $0.80 earnings per share. As a group, analysts expect that HealthEquity, Inc. will post 2.32 EPS for the current year.
About HealthEquity
(
Free Report)
HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.
Featured Stories

Before you consider HealthEquity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HealthEquity wasn't on the list.
While HealthEquity currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.